The Institute for Clinical and Economic Review (ICER), a drug pricing watchdog in the U.S., has ruled that novel oral migraine therapies have similar effectiveness but are not superior to triptans (5-HT 1B/1D agonists). Read More
Latest News
Natalizumab use in late pregnancy
February 19, 2020A new study reports that hematologic abnormalities may occur in one-third of infants exposed to natalizumab during the third trimester but treatment was generally safe (Triplett et al. Mult Scler Relat Disord 2020;40:101961). Read More
New drug approvals in 2020
February 5, 2020A number of new drugs for neurology and psychiatry are currently in review with regulatory authorities in the U.S. and Canada. The following summarizes some of the key therapies expected to be approved in 2020. Read More
FDA approves compassionate use of Ecstasy
January 29, 2020The U.S. Food and Drug Administration has granted Expanded Access to methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD), enabling some patients to undergo treatment before the drug is formally authorized. MDMA, known by the street names Ecstasy and Molly, was developed and patented by E. Merck (now EMD Serono) a century ago. It was used as an empathogen in psychotherapy during the 1970s but was labelled as a Schedule I controlled substance (no medical use) in 1985.